出版物

2005

Translational research in oncology comes timely.

Chow LWC and Toi M.
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S263  Details

Chemoprevention of colorectal cancer; the role of COX 2 inhibitors, from the bench to the bed-side

Arber N
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S332  Details

Correlation between Cox-2 related gene expressions and response to preoperative chemotherapy with celecoxib in primary breast cancer

Bando H , Chow LWC, Higashimoto M, Loo WT, Nakanishi C, Takebayashi Y and Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S317  Details

Prognostic significance of peritumoral vascular invasion in patients with invasive breast cancer

Bong JG , Choi JW, Ha YG, Lee YS, Park JH, Jeong MH, Lee HO and Oh HG
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S396  Details

Tumor angiogenesis and therapy

Cao Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S340-3  Details

Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression

Chan CML , Ma BBY, Wong SC and Chan ATC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S268-71  Details

Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergywith docosahexaenoic acid on the growth of human skin melanoma A-375 cells

Chiu LCM , Tong KF and Ooi VEC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S293-7  Details

Clinicopathologic characteristics of early (40-year-old or younger) onset infiltrating ductal carcinoma of the breast

Choi ES and Kim KC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S394  Details

Aberrant methylation of cyclooxygenase-2 in breast cancer patients

Chow LWC , Zhu L, Loo WTY and Lui ELH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S264-7  Details

Current directions for COX-2 inhibition in breast cancer

Chow LWC , Loo WTY, Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S281-4  Details

Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients

Chow LWC , Loo WTY , Wai CCY , Lui ELH , Zhu L and Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S298-301  Details

Serum lipid profiles in patients receiving endocrine treatment for breast cancer?the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial

Chow LWC , Cheng CWL ,Wong JLN and Toi M
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S302-5  Details

Natural killer cells in breast cancer cell growth and metastasis in SCID mice

Dewan MZ , Terunuma H, Ahmed S, Ohba K, Takada M, Tanaka Y, Toi M and Yamamoto N
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S375-9  Details

Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway

Dvory-Sobol H , Kazanov D and Arber N
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S370-4  Details

Metronomic therapy in recurrent and metastatic chemoresistant SCCHN: data from a pilot study

Gluck S , Lau H, Mackinnon J, Syme R and Gluck D
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S319  Details

Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition

Gluck S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S321-2  Details

Down syndrome critical region proteinl (DSCR1), a novel VEGF target gene that regulates expression of COX-2 on activated endothelial cells

Hesser BA , Liang XH, Camenisch G, Yang S, Lewin D, Scheller R, Ferrara N and Gerber HP
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S318  Details

Clinical experience for sentinel lymphadenectomy without further axillary dissection in stage I breast cancer

Jeong J , Lee IK, Jung WH, Ryu YH, Oh KK and Lee HD
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S393-4  Details

Expression of cyclin D1, vimentin and thyroglobulin in papillary thyroid cancer and its correlation with clinicobiological factors

Jong Na E and Kim KC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S395  Details

First-line bevacizumab (Avastin) with 5-fluorouracil/leucovorin prolongs progression-free survival in metastatic colorectal cancer (mCRC) patients who are not optimal candidates for irinotecan therapy. ASCO 2004: Abstract No. (3516)

Kabbinavar F , Schulz J, McCleod M, Patel T, Hamm J, Hecht J, Perrou B, Griffing S, Nelson B and Novotny W
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S348  Details

Inhibition effect of human angiogenesis of the cyclooxygenase (COX)-2 inhibitor with MMT cells

Kim SY and Kim TY
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S318  Details

RT-PCR amplification of CK 20 mRNA in the peripheral blood of breast cancer patients: correlation with established prognostic parameters

Kim J , Bae JW, Lee JB, Son GS and Koo BH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S380-3  Details

Prognostic factors in breast cancer patients following neoadjuvant chemotherapy

Kim JR and Chang ES
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S395-6  Details

Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer

Kuroi K , Toi M, Tsuda H, Kurosumi M and Akiyama F
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92  Details

Function of Survivin during embryonic angiogenesis and hematopoiesis in a zebrafish model

Kwan TTF , Cheung CL, Liang R and Leung AYH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S348-9  Details

Analysis of diagnostic and therapeutic efficacy of mammotome biopsy in breast tumor

Lee YA and Kim KC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S393  Details

Diffusion-weighted magnetic resonance imaging of nasopharyngeal carcinoma

Lee FKH , King AD, Yeung DKW, Ma B and Ahuja AT
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S395  Details

Curcumin synergistically potentiates the growth inhibitory and pro-apoptoticeffects of celecoxib in pancreatic adenocarcinoma cells

Lev-Ari S , Zinger H, Kazanov D, Yona D, Ben-Yosef
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S276-80  Details

CD24 and human carcinoma: tumor biological aspects

Lim SC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S351-4  Details

Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma

Lim SC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S366-9  Details

The significance of Cox-2 in sentinel lymph node of breast cancer

Liu TA , Yeh DC and Wu CC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S320  Details

The efficacy of Paclitaxel on solid tumour analysed by ATP bioluminescenceassay and VEGF expression: a translational research study

Loo WTY , Fong JHM, Cheung MNB, Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S337-9  Details

The value of bone marrow aspirates culture for the detection of bone marrow micrometastasis in breast cancer

Loo WTY , Fong JHM, Zhu L, Cheung MNB and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S384-6  Details

DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma

Lui ELH , Loo WTY, Zhu L, Cheung MNB and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S363-5  Details

NSABP adjuvant trial on the use of COX-2 inhibition in breast cancer

Mamounas EP
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S319-20  Details

Recent findings and future directions in breast cancer chemoprevention

Mamounas EP
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S332-3  Details

Update results of FEC followed by docetaxel neoadjuvant trials for primarybreast cancer

Ohno S , Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, et al.
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S323-4  Details

Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice

Olsen SR
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S306-10  Details

Neoadjuvant trials for discovery and validation of predictive markets?a new NSABP clinical trial paradigm

Paik S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S325  Details

Development and validation of multi-gene prognostic assay for ER+ breast cancer

Paik S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S394  Details

Dially disulfide from garlic induces apoptosis through caspase-dependent pathway in human breast cancer cell line, MCF-7

Park HL and Yang JH
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S394  Details

Roles of human vascular formation in tumor growth after cotransplantation of human microvascular endothelial and cancer cells to immunodeficiency mice

Ran Y , Zhong X, Zhang Y, Lou J, Yu L and Yang Z
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S349-50  Details

Pathological evaluation of angiogenesis in human tumor

Sasano H and Suzuki T
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S334-6  Details

COX-2 inhibitors act as radiosensitizer in tumor treatment

Sminia P , Kuipers G, Geldof A, Lafleur V and Slo
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S272-5  Details

COX and friends

Takebayashi Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S317-8  Details

The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma

Tang TCM , Poon RTP and Fan ST
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S311-6  Details

Vascular endothelial growth factor and its relationships with endogenousinhibitors in a breast cancer microenvironment manipulated by hormonaltherapy: a hypothetical consideration

Toi M , Bando H, Weich HA
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S344-7  Details

The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy

Trosko JE
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S326-31  Details

Detection of epithelial cell death in the body by cytokeratin 18 measurement

Ueno T , Toi M and Linder S
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S359-62  Details

Identification of IL-8 as a key factor in breast cancer invasion and angiogenesis

Wang SM and Lin Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S349  Details

Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts

Wu YL , Fu SL, Zhang YP, Qiao MM and Chen Y
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S289-92  Details

Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients

Zhang J , Ji J, Yuan F, Zhu L, Yan C, Yu YY, Liu
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S285-8  Details

Cyclooxygenase-2: possible predictor related to micrometastasis in breast cancer patients

Zhu L , Loo WTY and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S318  Details

Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes

Zhu L , Loo WTY and Chow LWC
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S355-8  Details

ootr.org

募集!! メンバーシップ

入会特典

学会登録割引

IJBM無料購読